DyslipidemiaCRESENDONCT01372956
Cholesterol Goal Attainment Rate and Its Associated Factors Among Dyslipidemic Patients on Lipid-lowering Drug Therapy in Korea
An observational study of Dyslipidemia, run by AstraZeneca at 20 sites in South Korea.
Trial summary
This is a multi-centre, cross-sectional, chart review study to investigate cholesterol goal attainment rates defined by modified NCEP-ATP III guidelines and define its possible determinants among Korean dyslipidemic patients Read more about this study
- Who is it for?
- Ages 19 years and older
- Conditions the study is for
- Dyslipidemia
- How many people
- 4,950 participants
- Where
- 20 sitesSouth Korea
- Study dates
- Aug 2011to Oct 2011
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Primary Care
Who may be able to join
- Patient who has a dyslipidemia with a lipid profile result within 3 months
- Patient who has a dyslipidemia without change of lipid lowering drug dosage during 3 months after lipid profile test.
Who cannot join
- Patient who involved in this study previously.
- Patient who participated in other clinical study with study drug within 90 days.
Trial locations and contacts
20 sites in 1 country.
20 sites in 1 country
South Korea20 sites
Research Site
Anyang-si, Gyeonggi-do
Research Site
Bucheon-si, Gyeonggi-do
Research Site
Bundang, Gyeonggi-do
Research Site
Busan, Busan
Research Site
Busan, Kyeongsangnam-do
Research Site
Changwon, Kyeongsangnam-do
Research Site
Cheonan, Chungcheongnam-do
Research Site
Cheongju-si, North Chungcheong
Research Site
Chuncheon, Gangwon-do
Research Site
Daegu, Kyeongsangbuk-do
Research Site
Deagu, Kyeongsangbuk-do
Research Site
Goyang-si, Gyeonggi-do
Research Site
Guri-si, Gyeonggi-do
Research Site
Gwangju, Gwangju
Research Site
Gwangju, Jeollabuk-do
Research Site
Iksan, Jeollabuk-do
Research Site
Incheon, Incheon
Research Site
Seoul, Seoul
Research Site
Tae, Chungcheongnam-do
Research Site
Uijeongbu-si, Gyeonggi-do
About this study
Official title: Cholesterol Goal Attainment Rate and Its Associated Factors Among Dyslipidemic Patients on Lipid-lowering Drug Therapy in Korea (CRESCENDO)
This is a multi-centre, cross-sectional, chart review study to investigate cholesterol goal attainment rates defined by modified NCEP-ATP III guidelines and define its possible determinants among Korean dyslipidemic patients
Read the detailed description
MC MD
- Conditions
- Dyslipidemia
- Keywords
- LDL-C, cholesterol, risk factor
- Medical subject headings
- Dyslipidemias
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Dyslipidemia | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cholesterol goal attainment rate according to NCEP-ATP III guideline
Measured: Once, at enrollment
Secondary outcomes (2)
Factors for cholesterol goal achievement: Age, Family history, smoking history, waist circumstance, etc.
Measured: Once, at enrollment
Cholesterol goal attainment rate related to CHD or disease history
Measured: Once, at enrollment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jun 2011 (estimated)
- Study startAug 2011
- Primary completionOct 2011
- Study completionOct 2011
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for DyslipidemiaStudies of the same condition, open and under way.
- More trials run by AstraZenecaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
- Enrolment
- 4,950 participants (actual)
Sponsor and investigators
- Lead sponsor
- AstraZeneca
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Jeong Ui Park, Principal investigator, Samsung Medical CenterJong sung Kim, Principal investigator, Seoul National University HospitalSung woo Park, Principal investigator, Kangbuk Samsung Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01372956
- Sponsor's protocol ID
- NIS-CKR-XXX-2011/1
- Acronym
- CRESENDO
- Status last verified
- Dec 2011
- First submitted
- 7 Jun 2011
- Last updated
- 22 Dec 2011
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Dec 2011. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Cholesterol Goal Attainment Rate and Its Associated Factors Among Dyslipidemic Patients on Lipid-lowering Drug Therapy in Korea (CRESCENDO)
- ClinicalTrials.gov ID
- NCT01372956
- Acronym / sponsor ID
- CRESENDO / NIS-CKR-XXX-2011/1
- Conditions
- Dyslipidemia
- Keywords
- LDL-C, cholesterol, risk factor
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 4,950 participants (actual)
- Lead sponsor
- AstraZenecaIndustry (pharma, biotech, devices)
- Study start
- Aug 2011
- Primary completion
- Oct 2011 (actual)
- Study completion
- Oct 2011 (actual)
- First posted
- 14 Jun 2011 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a multi-centre, cross-sectional, chart review study to investigate cholesterol goal attainment rates defined by modified NCEP-ATP III guidelines and define its possible determinants among Korean dyslipidemic patients
Detailed description
MC MD
Study design
- Observational model
- Case only
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Dyslipidemia | – | – |
Who may qualify
- Ages
- 19 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Primary Care
Key inclusion criteria (2 listed)
- Patient who has a dyslipidemia with a lipid profile result within 3 months
- Patient who has a dyslipidemia without change of lipid lowering drug dosage during 3 months after lipid profile test.
Key exclusion criteria (2 listed)
- Patient who involved in this study previously.
- Patient who participated in other clinical study with study drug within 90 days.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Cholesterol goal attainment rate according to NCEP-ATP III guideline
Time frame: Once, at enrollment
2 secondary outcomes
Factors for cholesterol goal achievement: Age, Family history, smoking history, waist circumstance, etc.
Time frame: Once, at enrollment
Cholesterol goal attainment rate related to CHD or disease history
Time frame: Once, at enrollment
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Dec 2011.
Related trials for Dyslipidemia
Active, not recruitingObservational study
Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD
Primary Hypercholesterolemia, Mixed Dyslipidemia
Not yet recruiting
Plasma Lipids-Dependent Vitamin E Metabolism During Dynamic Hyperlipidemia
Lipid Metabolism Disorders
Active, not recruitingObservational study
A Longitudinal Cohort Study to Evaluate Cardiovascular Risk Factors and Disease in Haiti
Hypertension, Diabetes
Active, not recruiting
Developing a Learning COmmunity to Increase eNgagemeNt and Enrollment in Cardiovascular Clinical Trials (CONNECT)
Cardiovascular Diseases, Hypertension
Active, not recruitingPhase 3
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
Primary Prevention of Atherosclerotic Cardiovascular Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jeong Ui Park principal investigator
Samsung Medical Center
Jong sung Kim principal investigator
Seoul National University Hospital
Sung woo Park principal investigator
Kangbuk Samsung Hospital
20 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Dyslipidemia, run by AstraZeneca at 20 sites in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Dec 2011. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 20 sites in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cholesterol goal attainment rate according to NCEP-ATP III guideline (time frame: Once, at enrollment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Dec 2011.